설사형 과민성 장 증후군 남성 환자에게 사용되는 ramosetron 의 경제성 평가
Economic Evaluation of Ramosetron in Male Patients with Diarrhea-predominant Irritable Bowel Syndrome in Korea
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
This study was conducted to analyze the cost-utility of ramosetron monotherapy, trimebutine monotherapy and trimebutine+loperamide combination therapy in male diarrhea-predominant patients with irritable bowel syndrome (IBS) in Korean healthcare setting. We constructed a decision-analytical model to estimate both total costs for each state of health and outcomes such as IBS-symptoms improvement for 3 and 6 months time horizon. Base analysis found that for ramosetron treatment with the price of KW910 for 5 μg tablet, incremental cost effectiveness ratios (ICERs, cost per quality-adjusted life day) were KW85,000 and KW62,000 for 3 months and 6 months, respectively, compared with trimebutine. But ramosetron was a dominant strategy when compared with trimebutine+loperamide for both 3 months and 6 months. Sensitivity analyses showed robust results for drug acquisition costs till ramosetron price of KW950/tablet. In conclusion, ramosetron was a cost-effective regimen compared with trimebutine or trimebutine+loperamide from the societal perspective.
Abstract
This study was conducted to analyze the cost-utility of ramosetron monotherapy, trimebutine monotherapy and trimebutine+loperamide combination therapy in male diarrhea-predominant patients with irritable bowel syndrome (IBS) in Korean healthcare setting. We constructed a decision-analytical model to estimate both total costs for each state of health and outcomes such as IBS-symptoms improvement for 3 and 6 months time horizon. Base analysis found that for ramosetron treatment with the price of KW910 for 5 μg tablet, incremental cost effectiveness ratios (ICERs, cost per quality-adjusted life day) were KW85,000 and KW62,000 for 3 months and 6 months, respectively, compared with trimebutine. But ramosetron was a dominant strategy when compared with trimebutine+loperamide for both 3 months and 6 months. Sensitivity analyses showed robust results for drug acquisition costs till ramosetron price of KW950/tablet. In conclusion, ramosetron was a cost-effective regimen compared with trimebutine or trimebutine+loperamide from the societal perspective.
참고문헌 (26)
- Kang JY, "Systematic review: the influence of geography and ethnicity in irritable bowel syndrome", Aliment Pharmacol Ther, 21(6), pp.663~673 (2005)
- "International Statistical Classification of Diseases and Related Health Problems 10th Revision"[URL]
- "Rome foundation, Rome criteria"[URL]
- Choi H, "Functional gastrointestinal disorders in patients with gastrointestinal symptoms", Korean J Gastroenterol, 33, pp.741~748 (1999)
- Han SH, "Prevalence of irritable bowel syndrome in Korea: population-based survey using the Rome II criteria", J Gastroenterol Hepatol, 21(11), pp.1687~1692 (2006)
- Park KS, "A survey about irritable bowel syndrome in South Korea: prevalence and observable organic abnormalities in IBS patients", Dig Dis Sci, 53(3), pp.704~711 (2008)
- "연구성과"[URL]
- Fauci AS, "Harrison's Online Featuring the complete contents of Harrison's Principles of Internal Medicine", 17e~
- Agrawal A, "Irritable bowel syndrome: diagnosis and management", BMJ, 332, pp.28083~ (2006)
- "2008년 진료비 통계지표"[URL]
- National Institute for Health and Clinical Excellence (NICE), "Irritable bowel syndrome in adult. Diagnosis and management of irritable bowel syndrome in adults in primary care", ~ (2008)
- Park HJ, "Evidence based guideline for diagnosis and treatment: therapeutic guideline for irritable bowel syndrome", Korean J Neurogastroenterol Motil, 11, pp.36~43 (2005)
- "의약품 정보"[URL]
- Matsueda K, "A phase II trial of the novel serotonin type 3 receptor antagonist ramosetron in Japanese male and female patients with diarrhea-predominant irritable bowel syndrome", Digestion, 77(3), pp.225~235 (2008)
- IBS Market Understanding Study Report, "Pharmaxogilvy Healthworld.IBS Market Understanding Study Report", ~ (2009)
- "IMS data MAT 06", 2009, 2009
- Matsueda K, "A randomized, double-blind, placebo-controlled clinical trial of the effectiveness of the novel serotonin type 3 receptor antagonist ramosetron in both male and female Japanese patients with diarrhea-predominant irritable bowel syndrome", Scand J Gastroenterol, 43(10), pp.1202~1211 (2008)
- Fielding JF, "Double blind trial of trimebutine in the irritable bowel syndrome", Ir Med J, 73(10), pp.377~379 (1980)
- YM060 - 장기투여시험 총괄보고서, "Astellas Report", ~, pp.Protocol No. 060-CL-203 (2006)
- Brennan S, "Developing valid and reliable health utilities in irritable bowel syndrome: Results from the IBS PROOF cohort", Am J Gastroenterol, 104(8), pp.1984~1991 (2009)
- 건강보험심사평가원, "의약품 주성분별 가중평균가격. 2009 상반기", ~ (2009)
- 건강보험심사평가원, "건강보험요양급여비용", ~ (2009)
- 보건복지부, "국민건강영양조사 (2005)", ~ (2006)
- "통계청. 소비자물가지수"[URL]
- Akehurst RL, "Health-related quality of life and cost impact of irritable bowel syndrome in a UK primary care setting", Pharmacoeconomics, 20(7), pp.455~462 (2002)
- Brun-Strang C, "Irritable bowel syndrome in France: quality of life, medical management, and costs: the Encoli study", Eur J Gastroenterol Hepatol, 19(12), pp.1097~103 (2007)